All In Biotech

Drug Trial Radar · NCT04539639

Clinical Study of Jaktinib in the Treatment of Patients With Moderate and Severe Atopic Dermatitis

A Multi-center,Randomized,Double-blind,Placebo,Parallel-controlled Phase II Clinical Study of Jaktinib Hydrochloride Tablets in the Treatment of Moderate and Severe Atopic Dermatitis Patients

Last checked: Nov 19, 2026Latest source record: Mar 24, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 166 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

166

Actual

Start

Dec 2, 2020

Primary completion

May 19, 2022

Study completion May 19, 2022

Sponsor

Sponsor type
Industry
First posted
Sep 7, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of Jaktinib in participants with moderate to severe atopic dermatitis.

Conditions

  • Atopic Dermatitis

Interventions

  • JaktinibDrug

    In the morning: 1 tablet of 50mg and 75mg placebo, 1 tablet of 50mg Jaktinib; In the evening: 1 tablet of 50mg and 75mg placebo, 1 tablet of 50mg Jaktinib.

  • JaktinibDrug

    In the morning: 2 tablet of 50mg placebo, 1 tablet of 75mg Jaktinib; In the evening: 2 tablet of 50mg placebo, 1 tablet of 75mg Jaktinib.

  • JaktinibDrug

    In the morning: 1 tablet of 75mg placebo, 2 tablet of 50mg Jaktinib; In the evening: 1 tablet of 75mg placebo, 2 tablet of 50mg Jaktinib.

  • placeboDrug

    In the morning: 2 tablet of 50mg placebo, 1 tablet of 75mg placebo;In the evening: 2 tablet of 50mg placebo, 1 tablet of 75mg placebo.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Achieving at least a 50% Reduction in Eczema Area and Severity Index (EASI 50) from BaselineTime frame: At Week 12

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The second xiangya hospital of central south university

    Changsha, Hunan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.